Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy.
Argnani L, Broccoli A, Pellegrini C, Fabbri A, Puccini B, Bruna R, Tisi MC, Masia F, Flenghi L, Nizzoli ME, Musso M, Salerno M, Scalzulli PR, Dessi' D, Ferrarini I, Pennese E, Lucchini E, Rossi FG, Minoia C, Gherlinzoni F, Musto P, Patti C, Stefoni V, Zinzani PL.
Argnani L, et al. Among authors: patti c.
Hemasphere. 2022 Nov 11;6(12):e798. doi: 10.1097/HS9.0000000000000798. eCollection 2022 Dec.
Hemasphere. 2022.
PMID: 36398133
Free PMC article.